Gilead sciences and arcus biosciences establish 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies

Gilead sciences and arcus biosciences establish 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.arcus biosciences inc - arcus to receive $175 million upfront payment.arcus biosciences inc - to receive $175 million upfront payment.arcus biosciences inc - arcus to receive $200 million equity investment and up to $1.6 billion plus in potential research and development funding.arcus biosciences inc - gilead to receive rights to opt-in to all programs in arcus's pipeline for length of collaboration.arcus biosciences inc - companies to co-commercialize gilead-optioned programs in u.s. with equal profit share.arcus biosciences inc - arcus to receive double-digit royalties outside u.s..arcus biosciences inc - agreement will provide ongoing funding to support arcus's research and development programs.arcus biosciences inc - if gilead opts-in to ab154 program, co eligible to receive up to $500 million in potential future milestones.arcus biosciences - gilead will further provide ongoing research and development support of up to $400 million over collaboration term.arcus biosciences inc - gilead's $200 million equity investment will be at a price per share of $33.54.arcus biosciences inc - gilead will have right to appoint two individuals to co's board upon closing of transaction.arcus biosciences inc - gilead will have right to purchase additional shares from arcus.
RCUS Ratings Summary
RCUS Quant Ranking